Published in J Am Soc Hypertens on April 22, 2010
Activation of hexosamine pathway impairs nitric oxide (NO)-dependent arteriolar dilations by increased protein O-GlcNAcylation. Vascul Pharmacol (2011) 1.45
O-GlcNAc signaling in the cardiovascular system. Circ Res (2010) 1.43
Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol (2011) 1.14
Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front Physiol (2012) 1.04
O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res (2010) 0.92
O-GlcNAcylation: a novel pathway contributing to the effects of endothelin in the vasculature. Am J Physiol Regul Integr Comp Physiol (2010) 0.84
O-GlcNAcylation and oxidation of proteins: is signalling in the cardiovascular system becoming sweeter? Clin Sci (Lond) (2012) 0.83
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells. Oncotarget (2016) 0.79
Short-term glucosamine infusion increases islet blood flow in anesthetized rats. Islets (2013) 0.75
Vascular O-GlcNAcylation augments reactivity to constrictor stimuli by prolonging phosphorylated levels of the myosin light chain. Braz J Med Biol Res (2014) 0.75
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci U S A (2004) 13.14
Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 8.48
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res (2001) 6.59
The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci U S A (2000) 4.55
The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci STKE (2005) 4.20
Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem (1991) 4.16
Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science (2001) 4.13
Probing the dynamics of O-GlcNAc glycosylation in the brain using quantitative proteomics. Nat Chem Biol (2007) 3.60
Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest (2001) 3.46
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36
Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem (2004) 3.35
Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem (1999) 3.13
Cell signaling, the essential role of O-GlcNAc! Biochim Biophys Acta (2006) 3.09
Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A (2002) 3.08
A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci U S A (2003) 2.97
Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics (2002) 2.88
O-linked N-acetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol Cell Proteomics (2006) 2.67
O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta (2004) 2.62
Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol (2004) 2.56
Identification of protein O-GlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides. Proc Natl Acad Sci U S A (2009) 2.54
The superhelical TPR-repeat domain of O-linked GlcNAc transferase exhibits structural similarities to importin alpha. Nat Struct Mol Biol (2004) 2.36
Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci U S A (2002) 2.32
Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc (2005) 2.27
Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry (2001) 2.24
O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J Biol Chem (2005) 2.22
Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain. Proc Natl Acad Sci U S A (2004) 2.17
A chemoenzymatic approach toward the rapid and sensitive detection of O-GlcNAc posttranslational modifications. J Am Chem Soc (2003) 2.14
Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab (2006) 2.12
Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation (2008) 2.11
Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity. J Biol Chem (2000) 2.05
Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation (2002) 2.02
Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A (2005) 1.93
Dynamic interplay between O-linked N-acetylglucosaminylation and glycogen synthase kinase-3-dependent phosphorylation. Mol Cell Proteomics (2007) 1.92
Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem (2002) 1.88
Glycosylation in the nucleus and cytoplasm. Annu Rev Biochem (1989) 1.87
O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst (2007) 1.86
AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol Chem (2008) 1.86
Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. J Biol Chem (1992) 1.82
Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage (2003) 1.79
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) (2007) 1.79
O-GlcNAc transferase is in a functional complex with protein phosphatase 1 catalytic subunits. J Biol Chem (2004) 1.77
Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system. Cardiovasc Res (2006) 1.74
Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest (1996) 1.72
Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol (2005) 1.68
Smooth muscle contraction and relaxation. Adv Physiol Educ (2003) 1.67
Structure-based design of beta 1,4-galactosyltransferase I (beta 4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: point mutation broadens beta 4Gal-T1 donor specificity. J Biol Chem (2002) 1.66
Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. J Biol Chem (2004) 1.66
O-GlcNAc turns twenty: functional implications for post-translational modification of nuclear and cytosolic proteins with a sugar. FEBS Lett (2003) 1.64
O-linked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem (2008) 1.64
A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol Biol Cell (2008) 1.64
Chemical approaches to understanding O-GlcNAc glycosylation in the brain. Nat Chem Biol (2008) 1.60
Identification and cloning of a novel family of coiled-coil domain proteins that interact with O-GlcNAc transferase. J Biol Chem (2002) 1.60
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
Vascular endothelin in hypertension. Vascul Pharmacol (2005) 1.52
Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol (2005) 1.52
Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer. Proc Natl Acad Sci U S A (2006) 1.51
Parallel identification of O-GlcNAc-modified proteins from cell lysates. J Am Chem Soc (2004) 1.48
Dynamic interplay between O-GlcNAc and O-phosphate: the sweet side of protein regulation. Curr Opin Struct Biol (2003) 1.46
A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol Life Sci (2003) 1.46
Regulation of the O-linked beta-N-acetylglucosamine transferase by insulin signaling. J Biol Chem (2008) 1.45
Detection of O-linked N-acetylglucosamine (O-GlcNAc) on cytoplasmic and nuclear proteins. Methods Enzymol (1994) 1.45
Identification of a nuclear variant of MGEA5, a cytoplasmic hyaluronidase and a beta-N-acetylglucosaminidase. Biochem Biophys Res Commun (2001) 1.44
Recombinant O-GlcNAc transferase isoforms: identification of O-GlcNAcase, yes tyrosine kinase, and tau as isoform-specific substrates. Glycobiology (2006) 1.44
Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol (2006) 1.42
Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci U S A (2000) 1.39
Methods in enzymology: O-glycosylation of proteins. Methods Enzymol (2005) 1.39
O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab (2008) 1.37
Glucosamine cardioprotection in perfused rat hearts associated with increased O-linked N-acetylglucosamine protein modification and altered p38 activation. Am J Physiol Heart Circ Physiol (2007) 1.37
Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes (1999) 1.37
Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am J Physiol Heart Circ Physiol (2008) 1.35
O-GlcNAc: a regulatory post-translational modification. Biochem Biophys Res Commun (2003) 1.35
Increasing O-GlcNAc levels: An overview of small-molecule inhibitors of O-GlcNAcase. Biochim Biophys Acta (2009) 1.32
Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology (2006) 1.32
GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels. J Am Chem Soc (2006) 1.28
Localization of O-GlcNAc modification on the serum response transcription factor. J Biol Chem (1992) 1.27
O-GlcNAc and the control of gene expression. Biochim Biophys Acta (1999) 1.27
Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol (2008) 1.26
Proteomic approaches to analyze the dynamic relationships between nucleocytoplasmic protein glycosylation and phosphorylation. Circ Res (2003) 1.26
N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol (2001) 1.25
O-linked N-acetylglucosamine levels in cerebellar neurons respond reciprocally to pertubations of phosphorylation. Eur J Biochem (1999) 1.24
Protein modification by O-linked GlcNAc reduces angiogenesis by inhibiting Akt activity in endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.22
Identification of O-linked N-acetylglucosamine proteins in rat skeletal muscle using two-dimensional gel electrophoresis and mass spectrometry. Mol Cell Proteomics (2004) 1.22
Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription. Prog Nucleic Acid Res Mol Biol (2003) 1.21
Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-kappa B pathway. FEBS Lett (2002) 1.21
Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol (2002) 1.20
Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes (2002) 1.17
Tagging-via-substrate strategy for probing O-GlcNAc modified proteins. J Proteome Res (2005) 1.14
O-linked N-acetylglucosamine: the "yin-yang" of Ser/Thr phosphorylation? Nuclear and cytoplasmic glycosylation. Adv Exp Med Biol (1995) 1.13
Hexosamine biosynthesis and protein O-glycosylation: the first line of defense against stress, ischemia, and trauma. Shock (2008) 1.12
Glucosamine administration during resuscitation improves organ function after trauma hemorrhage. Shock (2006) 1.12
Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine. J Neurosci Res (1995) 1.12
New insights into metabolic signaling and cell survival: the role of beta-O-linkage of N-acetylglucosamine. J Pharmacol Exp Ther (2008) 1.09
Hyperglycemia and inhibition of glycogen synthase in streptozotocin-treated mice: role of O-linked N-acetylglucosamine. J Biol Chem (2004) 1.09
Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. Hypertension (2009) 1.09
Identification of new O-GlcNAc modified proteins using a click-chemistry-based tagging. Anal Bioanal Chem (2008) 1.07
Neutrophils exhibit rapid agonist-induced increases in protein-associated O-GlcNAc. J Biol Chem (2004) 1.07
A cellular FRET-based sensor for beta-O-GlcNAc, a dynamic carbohydrate modification involved in signaling. J Am Chem Soc (2006) 1.05
Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate. J Am Chem Soc (2007) 1.04
RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A (2004) 2.53
Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) (2006) 1.87
Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol (2004) 1.86
Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats. Biochem Biophys Res Commun (2002) 1.53
Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats. Am J Hypertens (2009) 1.48
The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries. Crit Care Med (2009) 1.48
Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. Clin Sci (Lond) (2009) 1.47
Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension (2005) 1.47
Perivascular adipose tissue: more than just structural support. Clin Sci (Lond) (2012) 1.29
Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension (2002) 1.24
RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci (2010) 1.24
Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond) (2012) 1.23
ETA receptor blockade decreases vascular superoxide generation in DOCA-salt hypertension. Hypertension (2003) 1.20
Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther (2006) 1.18
Vascular Smooth Muscle Cell Signaling Mechanisms for Contraction to Angiotensin II and Endothelin-1. J Am Soc Hypertens (2010) 1.18
Cigarette smoking and erectile dysfunction: focus on NO bioavailability and ROS generation. J Sex Med (2008) 1.15
Increased activation of stromal interaction molecule-1/Orai-1 in aorta from hypertensive rats: a novel insight into vascular dysfunction. Hypertension (2008) 1.15
Reduced expression of SKCa and IKCa channel proteins in rat small mesenteric arteries during angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol (2007) 1.14
Hypertensive response to acute stress is attenuated in interleukin-6 knockout mice. Hypertension (2004) 1.14
Hypertension and RhoA/Rho-kinase signaling in the vasculature: highlights from the recent literature. Hypertension (2004) 1.14
Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.13
PYK2/PDZ-RhoGEF links Ca2+ signaling to RhoA. Arterioscler Thromb Vasc Biol (2009) 1.12
Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol (2004) 1.11
Molecular aspects of arterial smooth muscle contraction: focus on Rho. Exp Biol Med (Maywood) (2005) 1.11
c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension (2005) 1.10
Increased PDZ-RhoGEF/RhoA/Rho kinase signaling in small mesenteric arteries of angiotensin II-induced hypertensive rats. J Hypertens (2007) 1.10
Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. Hypertension (2009) 1.09
Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol (2013) 1.08
Sympathetic and angiotensin-dependent hypertension during cage-switch stress in mice. Am J Physiol Regul Integr Comp Physiol (2004) 1.07
Mitochondrial damage-associated molecular patterns and vascular function. Eur Heart J (2014) 1.06
Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition. J Cardiovasc Pharmacol (2005) 1.05
Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front Physiol (2012) 1.04
Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells. Mol Pharmacol (2005) 1.03
p38 Mitogen-activated protein kinase (MAPK) increases arginase activity and contributes to endothelial dysfunction in corpora cavernosa from angiotensin-II-treated mice. J Sex Med (2010) 1.03
Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther (2005) 1.02
Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovasc Res (2009) 1.00
Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med (2010) 1.00
The influence of perivascular adipose tissue on vascular homeostasis. Vasc Health Risk Manag (2013) 1.00
Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. J Pharmacol Exp Ther (2005) 0.99
Regional heterogeneity in acetylcholine-induced relaxation in rat vascular bed: role of calcium-activated K+ channels. Am J Physiol Heart Circ Physiol (2006) 0.98
Toll-like receptor 9 activation: a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in pre-eclampsia. Clin Sci (Lond) (2012) 0.98
Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-alpha on the endothelium of murine aorta. Am J Physiol Heart Circ Physiol (2010) 0.97
Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity. Hypertension (2009) 0.97
Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings. Am J Physiol Heart Circ Physiol (2007) 0.97
O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1. Hypertension (2009) 0.96
Endoplasmic reticulum stress contributes to aortic stiffening via proapoptotic and fibrotic signaling mechanisms. Hypertension (2013) 0.96
Early effects of high-fat diet on neurovascular function and focal ischemic brain injury. Am J Physiol Regul Integr Comp Physiol (2013) 0.95
Suppression of endoplasmic reticulum stress improves endothelium-dependent contractile responses in aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol (2013) 0.95
Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension (2008) 0.95
NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction. J Sex Med (2008) 0.95
Endothelin, sex and hypertension. Clin Sci (Lond) (2008) 0.95
Increased nitric oxide synthase activity and Hsp90 association in skeletal muscle following chronic exercise. Eur J Appl Physiol (2008) 0.95
Emerging role for TNF-α in erectile dysfunction. J Sex Med (2010) 0.93
Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology (2003) 0.93
Increased vascular O-GlcNAcylation augments reactivity to constrictor stimuli - VASOACTIVE PEPTIDE SYMPOSIUM. J Am Soc Hypertens (2010) 0.92
O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res (2010) 0.92
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation. J Cardiovasc Pharmacol (2010) 0.91
Rho-kinase inhibition reduces pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. Am J Physiol Renal Physiol (2009) 0.91
Transient receptor potential melastatin 7 (TRPM7) cation channels, magnesium and the vascular system in hypertension. Circ J (2010) 0.91
Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K+ channels in ETB-induced relaxation. Br J Pharmacol (2005) 0.91
P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1 beta release. J Pharmacol Exp Ther (2008) 0.90
Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biol Res Nurs (2002) 0.90
Neurophysiological basis of penile erection. Acta Pharmacol Sin (2007) 0.90
Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension. J Sex Med (2008) 0.90
Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension (2006) 0.90
Arginase 1 mediates increased blood pressure and contributes to vascular endothelial dysfunction in deoxycorticosterone acetate-salt hypertension. Front Immunol (2013) 0.89
Testosterone and vascular function in aging. Front Physiol (2012) 0.89
Hypotensive action of naturally occurring diterpenes: a therapeutic promise for the treatment of hypertension. Fitoterapia (2010) 0.89
Determination of adenosine effects and adenosine receptors in murine corpus cavernosum. J Pharmacol Exp Ther (2007) 0.89
ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension (2004) 0.89
Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors? Expert Opin Ther Targets (2008) 0.89
Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation. Cardiovasc Res (2009) 0.89
Conjugated equine estrogen treatment corrected the exacerbated aorta oxidative stress in ovariectomized spontaneously hypertensive rats. Steroids (2012) 0.89
Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats. Am J Hypertens (2004) 0.89
Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake. Am J Physiol Regul Integr Comp Physiol (2011) 0.89
New insights into hypertension-associated erectile dysfunction. Curr Opin Nephrol Hypertens (2012) 0.89
Comparative pharmacological analysis of Rho-kinase inhibitors and identification of molecular components of Ca2+ sensitization in the rat lower urinary tract. Biochem Pharmacol (2007) 0.88
Targets for the treatment of erectile dysfunction: is NO/cGMP still the answer? Recent Pat Cardiovasc Drug Discov (2007) 0.88
Nitric oxide inhibits RhoA/Rho-kinase signaling to cause penile erection. Eur J Pharmacol (2002) 0.88
Penile erection requires association of soluble guanylyl cyclase with endothelial caveolin-1 in rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol (2005) 0.88
Erectile dysfunction in young non-obese type II diabetic Goto-Kakizaki rats is associated with decreased eNOS phosphorylation at Ser1177. J Sex Med (2010) 0.88
Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse. J Sex Med (2008) 0.88
Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension (2012) 0.87
Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1. Hypertension (2011) 0.87